To confirm the inhibitory activity of sotorasib in the cell lines used, cell extracts of control vs. sotorasib-treated NSCLC cells were immunoblotted for phospho-ERK1/2. The gene discussed is MAPK3; the disease is non-small cell lung carcinoma.